Nexalis Issues Settlement Options To Linlithgow Family Office
NX1: $0.008 +0.00% · MC: $2M
Nexalis Therapeutics has issued 15 million unlisted options to Linlithgow Family Office as settlement for funding received under its former facility. The options replace 38.4 million older options, which were cancelled when the facility was terminated; the settlement leaves no repayment obligation to the lender.

Comments